Stock listing

Shenzhen:301569 Novast Laboratories Ltd (联亚药业) 股价

Follow Novast Laboratories Ltd into a list and get an email when it puts out news.

Share price · SZSE:301569

¥15.01 CNY -0.99 (-6.2%)

Close on Nov 20, 2026

Past month -57.3% · daily closes, Oct 15, 2026 – Nov 20, 2026, adjusted for splits
Day range
¥15.01 – ¥15.87 CNYNov 20, 2026
Volume
14.54M sharesNov 20, 2026
Market cap
¥13.38B CNYAt the close on Nov 20, 2026 · price × 891.6M shares outstanding
Traded on an average day
¥882.6M CNYMedian day 40.28M shares · last 3 months, Oct 15, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Oct 15, 2026 – Nov 20, 2026 · SZSE:301569 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥15.01-0.99-6.2%¥15.50¥15.87¥15.0114,544,954
¥16.00-0.73-4.4%¥16.80¥16.80¥15.6619,797,353
¥16.73-0.51-3.0%¥17.04¥17.33¥16.6017,433,144
¥17.24-0.75-4.2%¥17.76¥18.00¥17.1717,079,542
¥17.99-1.61-8.2%¥19.00¥19.40¥17.7732,805,263
¥19.60+0.34+1.8%¥19.06¥19.79¥19.0633,536,992
¥19.26-0.34-1.7%¥19.00¥19.37¥18.6632,785,398
¥19.60+0.77+4.1%¥19.16¥20.27¥19.1634,708,316
¥18.83-0.44-2.3%¥19.00¥19.65¥18.6230,981,650
¥19.27-2.52-11.6%¥20.25¥21.10¥19.1943,187,931
¥21.79+0.68+3.2%¥20.50¥22.03¥20.1155,426,398
¥21.11+1.51+7.7%¥19.62¥23.51¥19.6258,244,887
¥19.60+0.32+1.7%¥18.85¥19.68¥18.4141,124,676
¥19.28+1.06+5.8%¥18.54¥19.35¥17.6039,431,816
¥18.22+0.44+2.5%¥17.48¥19.45¥17.4843,387,141
¥17.78-1.20-6.3%¥18.65¥19.48¥17.5033,296,027
¥18.98+1.04+5.8%¥17.90¥19.38¥17.3938,969,895
¥17.94-0.95-5.0%¥18.61¥18.89¥17.8335,316,570
¥18.89+0.47+2.6%¥17.69¥19.58¥17.5344,833,598
¥18.42+0.92+5.3%¥16.98¥18.74¥16.7548,733,816
¥17.50-2.56-12.8%¥19.19¥19.46¥17.5047,944,281
¥20.06-2.03-9.2%¥21.01¥22.59¥20.0252,069,328
¥22.09+0.02+0.1%¥22.45¥23.76¥22.0048,601,734
¥22.07-3.10-12.3%¥23.88¥25.90¥21.9057,868,695
¥25.17-9.95-28.3%¥32.00¥36.00¥25.0073,074,492
¥35.12——¥27.00¥42.15¥27.0093,230,797
Ticker
Shenzhen:301569
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Shenzhen
Currency
CNY

Novast Laboratories Ltd on 6ix

Sector
Health care
Industry
Pharmaceuticals

Valuation

P/E 43.0× against a median of 20.5×: 9th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥11.97B CNY
P/E
43.0×
EV/sales
11.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.9×
Gross margin
60.3%
Operating margin
37.3%
Net margin
30.8%
Debt to equity
0.0×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Novast Laboratories Ltd · SZSE:301569US$2.01BUS$1.80B43.0×11.9×n/a5.9×30.8%0.0×n/a
Alembic Pharmaceuticals Limited · NSE:APLLTDUS$2.21BUS$2.34B24.3×2.6×15.3×3.4×10.0%0.3×n/a
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A · SZSE:300255US$2.18BUS$2.27Bn/a16.3×n/a12.5×−37.7%0.6×n/a
Zhejiang Hisun Pharmaceutical Co., Ltd. Class A · SSE:600267US$2.15BUS$1.97B11.7×1.4×n/a1.5×13.4%0.0×n/a
Henan Lingrui Pharmaceutial Co., Ltd. Class A · SSE:600285US$2.04BUS$1.89B16.4×3.2×n/a3.9×20.9%0.0×n/a
Aurinia Pharmaceuticals Inc · NASDAQ:AUPHUS$1.97BUS$1.92B6.3×6.0×n/a3.0×97.7%0.0×0.64
Harmony Biosciences Holdings, Inc. · NASDAQ:HRMYUS$1.91BUS$1.29B10.7×1.3×5.4×1.8×18.1%0.1×0.57
Alivus Life Sciences Ltd · NSE:ALIVUSUS$1.90BUS$1.80B26.3×6.2×18.1×4.9×24.9%0.0×n/a
Pfizer Limited · NSE:PFIZERUS$1.90BUS$1.24B20.5×4.3×11.8×4.0×32.4%0.0×n/a
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A · SSE:603707US$1.90BUS$1.52B29.8×2.5×n/a1.8×10.4%0.0×n/a
Shenzhen Kangtai Biological Products Co. Ltd. Class A · SZSE:300601US$1.80BUS$1.74B103×4.7×n/a1.2×4.8%0.2×n/a
Median of the othersUS$1.94BUS$1.84B20.5×3.8×13.6×3.2×15.7%0.0×0.61

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022
Revenue895.5M866.2M700.4M550.1M
Cost of revenue396.4M394.2M348.9M270.4M
Gross profit499.0M472.0M351.5M279.7M
Research and development101.0M101.7M88.7M102.9M
Selling, general and administrative167.5M280.0M447.6M198.2M
Operating income267.7M257.5M120.7M48.7M
Depreciation and amortization35.9M34.6M34.5M32.7M
EBITDA303.6M292.1M155.2M81.4M
Income before tax263.1M290.1M136.1M130.2M
Net income227.8M260.1M115.8M113.0M
Earnings per share, basic0.300.340.150.15

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents1.10B863.1M638.1M475.6M
Short-term investments100.2M146.2M170.4M228.1M
Receivables173.0M132.1M113.0M80.0M
Inventory214.6M228.0M262.0M262.6M
Current assets1.62B1.41B1.23B1.10B
Total assets2.29B2.05B1.75B1.53B
Accounts payable13.0M8.93M9.18M3.09M
Current liabilities166.6M162.8M112.0M83.6M
Total liabilities283.9M261.4M225.9M200.9M
Shareholders' equity2.01B1.79B1.53B1.33B
Shares outstanding757.9M757.9M757.9M757.9M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations322.6M267.0M200.9M209.2M
Capital spending-75.3M-105.9M-127.0M-69.8M
Free cash flow247.3M161.2M74.0M139.4M
Dividends paid-68.0M
Change in cash-10.6M60.5M-104.7K-16.7M

Open Financials

Cap table

Built by 6ix from Novast Laboratories Ltd’s releases

Common shares
891,597,091
Fully diluted
891,597,091

Fully diluted

LineShares
Common shares891,597,091

Share count over time

CountShares
Nov 22, 2026891,597,091

Open Cap table

Log in to ask 6ix AI your own questions about Novast Laboratories Ltd.